Neumora

Neumora is a clinical-stage biotechnology company focused on developing precision medicines for brain diseases, including neuropsychiatric and neurodegenerative disorders. The company was founded in November 2019 as RBNC Therapeutics and changed its name to Neumora Therapeutics in October 2021. Its lead program is navacaprant, an oral kappa opioid receptor antagonist in Phase 3 development for major depressive disorder. Neumora also has earlier-stage programs targeting agitation in Alzheimer's disease, schizophrenia, obesity, Parkinson's disease, and amyotrophic lateral sclerosis. The company combines neuroscience drug development with a proprietary precision neuroscience platform that uses Data Biopsy Signatures and Precision Phenotypes to match targeted therapies to patient subtypes. Neumora is publicly traded on Nasdaq and operates from Watertown, Massachusetts.